Coupling interferon to a synthetic PEG molecule could increase the therapeutic’s dosing schedule from every other day to every one to two weeks, according to researchers who believe the technology has blockbuster potential.
Modigene says that data from a trial of a Schering-Plough's (SP)
fertility stimulation hormone (FSH-CTP) confirms that carboxyl
terminal peptide (CTP) modification can extend the therapeutic
duration of protein drugs.
Despite the popularity of transgenics and the potential it is seen
to hold for the future of biopharmaceutical production, Viragen has
decided to drop development of its OVA system - therapeutic protein
production in transgenic hen...
Researchers have managed to rear a flock of transgenic hens capable
of producing eggs that express remarkably high levels of a protein
used for the treatment of hepatitis C, potentially creating a
cheaper and more efficient rival...
BioPartners has failed to bring its second biosimilar product into
Europe after the European Agency for the Evaluation of Medicinal
Products (EMEA) issued a negative opinion on its hepatitis C drug,
citing characterisation, manufacturing...
The interest in Syntonix' SynFusion and Transceptor technologies
intensified as Boehringer Ingelheim became the second
pharmaceutical company to use this technology to optimise its
therapeutic peptides for inhalation.
BioPartners, currently leading the line amongst companies trying to
bring copies of off-patent biologic drugs to the European market,
has licensed a needle-free delivery technology for its human growth
hormone (hGH) product.
Swiss biopharmaceuticals company BioPartners has filed its first
application in Europe for a generic version of interferon alpha, a
biological drug. If approved, the 'biosimilar' could be on the
market as early as next year.